(0.32%) 5 116.31 points
(0.30%) 38 354 points
(0.36%) 15 986 points
(-0.98%) $83.03
(5.36%) $2.03
(0.27%) $2 353.60
(0.39%) $27.64
(4.13%) $960.15
(-0.27%) $0.932
(-0.46%) $10.97
(-0.57%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform...
Stats | |
---|---|
本日の出来高 | 1.75M |
平均出来高 | 263 314 |
時価総額 | 2.33M |
EPS | $0 ( 2024-03-18 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0194 |
ATR14 | $0.141 (69.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-05 | Lau Johnson Yiu Nam | Buy | 8 382 | Common Stock |
2023-05-05 | Kwan Rudolf | Buy | 3 603 | Common Stock |
2023-05-05 | Cook Timothy Devere | Buy | 368 | Common Stock |
2023-04-21 | Wu Jinn | Buy | 6 513 | Common Stock |
2023-04-21 | Vierling John | Buy | 6 513 | Common Stock |
INSIDER POWER |
---|
94.72 |
Last 100 transactions |
Buy: 1 577 577 | Sell: 76 746 |
ボリューム 相関
Athenex Inc 相関
10 最も負の相関 | |
---|---|
SWAV | -0.955 |
ISRG | -0.954 |
HBIO | -0.95 |
LMRKO | -0.948 |
TYHT | -0.946 |
VRTX | -0.945 |
CREX | -0.943 |
LMRKP | -0.942 |
ALXN | -0.942 |
ITCI | -0.94 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Athenex Inc 相関 - 通貨/商品
Athenex Inc 財務諸表
Annual | 2022 |
収益: | $102.82M |
総利益: | $26.70M (25.97 %) |
EPS: | $-15.13 |
FY | 2022 |
収益: | $102.82M |
総利益: | $26.70M (25.97 %) |
EPS: | $-15.13 |
FY | 2021 |
収益: | $120.18M |
総利益: | $37.78M (31.43 %) |
EPS: | $-1.920 |
FY | 2020 |
収益: | $144.39M |
総利益: | $49.04M (33.96 %) |
EPS: | $-1.720 |
Financial Reports:
No articles found.
Athenex Inc
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。